JP4552076B2 - 喘息および関連疾患を含むアトピー性アレルギーの治療および診断に有用なｉｌ−９受容体変異体 - Google Patents

喘息および関連疾患を含むアトピー性アレルギーの治療および診断に有用なｉｌ−９受容体変異体 Download PDF

Info

Publication number: JP4552076B2
Authority: JP; Japan
Prior art keywords: receptor; cells; asthma; human; dna
Prior art date: 1996-12-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP52573798A

Other languages

English (en)

Japanese (ja)

Other versions

JP2002514911A (ja

JP2002514911A5 (de

Inventor

レヴィット，ロイ，クリフォード

グラッソ，ルイージ

ニコライデス，ニコラス，シー．

ハルロイド，ケニス，ジェイ．

Original Assignee

ジェネーラコーポレーション

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-02

Filing date

1997-12-02

Publication date

2010-09-29

1997-12-02 Application filed by ジェネーラコーポレーション filed Critical ジェネーラコーポレーション

1997-12-02 Priority claimed from PCT/US1997/021992 external-priority patent/WO1998024904A2/en

2002-05-21 Publication of JP2002514911A publication Critical patent/JP2002514911A/ja

2005-08-11 Publication of JP2002514911A5 publication Critical patent/JP2002514911A5/ja

2010-09-29 Application granted granted Critical

2010-09-29 Publication of JP4552076B2 publication Critical patent/JP4552076B2/ja

2017-12-02 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

208000006673 asthma Diseases 0.000 title claims abstract description 90
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 44
201000010099 disease Diseases 0.000 title claims description 43
206010003645 Atopy Diseases 0.000 title abstract description 27
238000011282 treatment Methods 0.000 title abstract description 22
238000003745 diagnosis Methods 0.000 title abstract description 10
108010038414 Interleukin-9 Receptors Proteins 0.000 title description 124
102000010682 Interleukin-9 Receptors Human genes 0.000 title description 110
206010020751 Hypersensitivity Diseases 0.000 title description 25
230000007815 allergy Effects 0.000 title description 24
208000026935 allergic disease Diseases 0.000 title description 17
238000000034 method Methods 0.000 claims abstract description 54
108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
150000007523 nucleic acids Chemical class 0.000 claims description 11
102000039446 nucleic acids Human genes 0.000 claims description 8
108020004707 nucleic acids Proteins 0.000 claims description 8
208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
208000013931 susceptibility to asthma Diseases 0.000 claims 1
108090000623 proteins and genes Proteins 0.000 abstract description 87
108020004705 Codon Proteins 0.000 abstract description 53
102000004169 proteins and genes Human genes 0.000 abstract description 53
208000024711 extrinsic asthma Diseases 0.000 abstract description 31
150000001413 amino acids Chemical class 0.000 abstract description 20
238000012217 deletion Methods 0.000 abstract description 19
230000037430 deletion Effects 0.000 abstract description 19
239000003814 drug Substances 0.000 abstract description 17
239000002243 precursor Substances 0.000 abstract description 11
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract description 7
210000004027 cell Anatomy 0.000 description 109
102000000585 Interleukin-9 Human genes 0.000 description 64
108010002335 Interleukin-9 Proteins 0.000 description 64
102000005962 receptors Human genes 0.000 description 50
108020003175 receptors Proteins 0.000 description 50
235000018102 proteins Nutrition 0.000 description 48
108020004414 DNA Proteins 0.000 description 47
102000053602 DNA Human genes 0.000 description 47
239000002299 complementary DNA Substances 0.000 description 30
230000014509 gene expression Effects 0.000 description 30
230000006870 function Effects 0.000 description 28
101001055219 Homo sapiens Interleukin-9 receptor Proteins 0.000 description 26
150000001875 compounds Chemical class 0.000 description 25
125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 22
108700028369 Alleles Proteins 0.000 description 21
210000000349 chromosome Anatomy 0.000 description 21
230000035772 mutation Effects 0.000 description 21
241000699666 Mus <mouse, genus> Species 0.000 description 20
210000001744 T-lymphocyte Anatomy 0.000 description 20
235000001014 amino acid Nutrition 0.000 description 19
230000027455 binding Effects 0.000 description 19
239000002773 nucleotide Substances 0.000 description 19
125000003729 nucleotide group Chemical group 0.000 description 19
229940024606 amino acid Drugs 0.000 description 18
102000004127 Cytokines Human genes 0.000 description 16
108090000695 Cytokines Proteins 0.000 description 16
230000003321 amplification Effects 0.000 description 16
238000004458 analytical method Methods 0.000 description 16
238000003199 nucleic acid amplification method Methods 0.000 description 16
230000037361 pathway Effects 0.000 description 16
102000004388 Interleukin-4 Human genes 0.000 description 15
108090000978 Interleukin-4 Proteins 0.000 description 15
239000005557 antagonist Substances 0.000 description 15
108091008109 Pseudogenes Proteins 0.000 description 14
102000057361 Pseudogenes Human genes 0.000 description 14
230000010083 bronchial hyperresponsiveness Effects 0.000 description 14
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
239000002953 phosphate buffered saline Substances 0.000 description 14
108090000765 processed proteins & peptides Proteins 0.000 description 14
230000004044 response Effects 0.000 description 14
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 13
238000003556 assay Methods 0.000 description 13
239000003446 ligand Substances 0.000 description 13
239000000047 product Substances 0.000 description 13
210000002966 serum Anatomy 0.000 description 13
208000024891 symptom Diseases 0.000 description 13
108700024394 Exon Proteins 0.000 description 11
108010002350 Interleukin-2 Proteins 0.000 description 11
102000000588 Interleukin-2 Human genes 0.000 description 11
102000004196 processed proteins & peptides Human genes 0.000 description 11
239000000243 solution Substances 0.000 description 11
101001055216 Homo sapiens Interleukin-9 Proteins 0.000 description 10
238000001514 detection method Methods 0.000 description 10
210000003630 histaminocyte Anatomy 0.000 description 10
102000052627 human IL9 Human genes 0.000 description 10
230000026731 phosphorylation Effects 0.000 description 10
238000006366 phosphorylation reaction Methods 0.000 description 10
108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
239000004475 Arginine Substances 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
108091092195 Intron Proteins 0.000 description 9
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 9
230000004913 activation Effects 0.000 description 9
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 9
235000009697 arginine Nutrition 0.000 description 9
230000001419 dependent effect Effects 0.000 description 9
230000000694 effects Effects 0.000 description 9
229940028885 interleukin-4 Drugs 0.000 description 9
108020004999 messenger RNA Proteins 0.000 description 9
229920001184 polypeptide Polymers 0.000 description 9
230000035755 proliferation Effects 0.000 description 9
238000012360 testing method Methods 0.000 description 9
108091003079 Bovine Serum Albumin Proteins 0.000 description 8
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
230000003993 interaction Effects 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
239000012528 membrane Substances 0.000 description 8
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
102000054765 polymorphisms of proteins Human genes 0.000 description 8
230000000638 stimulation Effects 0.000 description 8
239000000126 substance Substances 0.000 description 8
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 8
238000001262 western blot Methods 0.000 description 8
102000000646 Interleukin-3 Human genes 0.000 description 7
108010002386 Interleukin-3 Proteins 0.000 description 7
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 7
239000013566 allergen Substances 0.000 description 7
208000010668 atopic eczema Diseases 0.000 description 7
210000003719 b-lymphocyte Anatomy 0.000 description 7
230000000875 corresponding effect Effects 0.000 description 7
238000011161 development Methods 0.000 description 7
230000018109 developmental process Effects 0.000 description 7
239000013604 expression vector Substances 0.000 description 7
239000012634 fragment Substances 0.000 description 7
230000002068 genetic effect Effects 0.000 description 7
229940118526 interleukin-9 Drugs 0.000 description 7
239000013612 plasmid Substances 0.000 description 7
230000001105 regulatory effect Effects 0.000 description 7
235000004400 serine Nutrition 0.000 description 7
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
206010061218 Inflammation Diseases 0.000 description 6
125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 6
239000012980 RPMI-1640 medium Substances 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000000872 buffer Substances 0.000 description 6
229940079593 drug Drugs 0.000 description 6
239000012894 fetal calf serum Substances 0.000 description 6
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
239000000203 mixture Substances 0.000 description 6
230000004043 responsiveness Effects 0.000 description 6
150000003355 serines Chemical class 0.000 description 6
238000010186 staining Methods 0.000 description 6
229940124597 therapeutic agent Drugs 0.000 description 6
239000013598 vector Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 5
102000013563 Acid Phosphatase Human genes 0.000 description 5
108010051457 Acid Phosphatase Proteins 0.000 description 5
108020004635 Complementary DNA Proteins 0.000 description 5
241000699800 Cricetinae Species 0.000 description 5
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 5
108010036949 Cyclosporine Proteins 0.000 description 5
230000004163 JAK-STAT signaling pathway Effects 0.000 description 5
238000012300 Sequence Analysis Methods 0.000 description 5
239000000556 agonist Substances 0.000 description 5
230000006907 apoptotic process Effects 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
229960001265 ciclosporin Drugs 0.000 description 5
238000010367 cloning Methods 0.000 description 5
238000013461 design Methods 0.000 description 5
230000003828 downregulation Effects 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
230000037433 frameshift Effects 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 5
229960002329 methacholine Drugs 0.000 description 5
230000009257 reactivity Effects 0.000 description 5
230000002441 reversible effect Effects 0.000 description 5
102200082402 rs751610198 Human genes 0.000 description 5
210000003491 skin Anatomy 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 4
108091026890 Coding region Proteins 0.000 description 4
241000701022 Cytomegalovirus Species 0.000 description 4
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
241000243780 Heligmosomoides polygyrus Species 0.000 description 4
102000003814 Interleukin-10 Human genes 0.000 description 4
108090000174 Interleukin-10 Proteins 0.000 description 4
102000000743 Interleukin-5 Human genes 0.000 description 4
108010002616 Interleukin-5 Proteins 0.000 description 4
101001055215 Mus musculus Interleukin-9 Proteins 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
241000700605 Viruses Species 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 4
230000000172 allergic effect Effects 0.000 description 4
229960001230 asparagine Drugs 0.000 description 4
238000001574 biopsy Methods 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
210000004899 c-terminal region Anatomy 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
230000004663 cell proliferation Effects 0.000 description 4
230000008859 change Effects 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
229930182912 cyclosporin Natural products 0.000 description 4
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
230000007613 environmental effect Effects 0.000 description 4
210000003979 eosinophil Anatomy 0.000 description 4
229940100602 interleukin-5 Drugs 0.000 description 4
238000013507 mapping Methods 0.000 description 4
238000010369 molecular cloning Methods 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
238000007894 restriction fragment length polymorphism technique Methods 0.000 description 4
238000010839 reverse transcription Methods 0.000 description 4
239000000523 sample Substances 0.000 description 4
238000012216 screening Methods 0.000 description 4
229930024421 Adenine Natural products 0.000 description 3
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
201000004624 Dermatitis Diseases 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000028180 Glycophorins Human genes 0.000 description 3
108091005250 Glycophorins Proteins 0.000 description 3
101150030450 IRS1 gene Proteins 0.000 description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
101001055214 Mus musculus Interleukin-9 receptor Proteins 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
238000012408 PCR amplification Methods 0.000 description 3
239000012083 RIPA buffer Substances 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
230000009471 action Effects 0.000 description 3
229960000643 adenine Drugs 0.000 description 3
230000009285 allergic inflammation Effects 0.000 description 3
230000008485 antagonism Effects 0.000 description 3
239000000427 antigen Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
238000001516 cell proliferation assay Methods 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
230000002759 chromosomal effect Effects 0.000 description 3
230000001086 cytosolic effect Effects 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000000499 gel Substances 0.000 description 3
208000005017 glioblastoma Diseases 0.000 description 3
230000013595 glycosylation Effects 0.000 description 3
238000006206 glycosylation reaction Methods 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
238000003119 immunoblot Methods 0.000 description 3
238000001114 immunoprecipitation Methods 0.000 description 3
238000011065 in-situ storage Methods 0.000 description 3
208000027866 inflammatory disease Diseases 0.000 description 3
238000002955 isolation Methods 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
230000004199 lung function Effects 0.000 description 3
TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 3
239000000463 material Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
238000003752 polymerase chain reaction Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
230000009696 proliferative response Effects 0.000 description 3
208000023504 respiratory system disease Diseases 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 2
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
108020005029 5' Flanking Region Proteins 0.000 description 2
108090000672 Annexin A5 Proteins 0.000 description 2
102000004121 Annexin A5 Human genes 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
241000222120 Candida <Saccharomycetales> Species 0.000 description 2
229930105110 Cyclosporin A Natural products 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
101000715050 Homo sapiens Thromboxane A2 receptor Proteins 0.000 description 2
101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
108010001127 Insulin Receptor Proteins 0.000 description 2
102100036721 Insulin receptor Human genes 0.000 description 2
108010038486 Interleukin-4 Receptors Proteins 0.000 description 2
102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 description 2
101150069380 JAK3 gene Proteins 0.000 description 2
229930064664 L-arginine Natural products 0.000 description 2
235000014852 L-arginine Nutrition 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
241001529936 Murinae Species 0.000 description 2
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
241000235648 Pichia Species 0.000 description 2
108010017324 STAT3 Transcription Factor Proteins 0.000 description 2
102000004495 STAT3 Transcription Factor Human genes 0.000 description 2
101150099493 STAT3 gene Proteins 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 2
208000000389 T-cell leukemia Diseases 0.000 description 2
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
102000003938 Thromboxane Receptors Human genes 0.000 description 2
108090000300 Thromboxane Receptors Proteins 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 2
230000001594 aberrant effect Effects 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
238000007792 addition Methods 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
238000000137 annealing Methods 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
239000011324 bead Substances 0.000 description 2
229940125388 beta agonist Drugs 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
210000002230 centromere Anatomy 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000013599 cloning vector Substances 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000007123 defense Effects 0.000 description 2
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000000799 fluorescence microscopy Methods 0.000 description 2
230000004927 fusion Effects 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
230000012010 growth Effects 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 2
229940097277 hygromycin b Drugs 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000036737 immune function Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000010249 in-situ analysis Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000006166 lysate Substances 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
239000003550 marker Substances 0.000 description 2
208000008585 mastocytosis Diseases 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000003226 mitogen Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
208000025113 myeloid leukemia Diseases 0.000 description 2
239000013642 negative control Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
230000008520 organization Effects 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
230000004481 post-translational protein modification Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
229960005205 prednisolone Drugs 0.000 description 2
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
229920002477 rna polymer Polymers 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000011896 sensitive detection Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
210000003765 sex chromosome Anatomy 0.000 description 2
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
241000894007 species Species 0.000 description 2
210000000130 stem cell Anatomy 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
108091035539 telomere Proteins 0.000 description 2
210000003411 telomere Anatomy 0.000 description 2
102000055501 telomere Human genes 0.000 description 2
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
150000003573 thiols Chemical class 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
239000012049 topical pharmaceutical composition Substances 0.000 description 2
230000005030 transcription termination Effects 0.000 description 2
238000001890 transfection Methods 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-L 4-nitrophenyl phosphate(2-) Chemical compound [O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-L 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
208000012657 Atopic disease Diseases 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
238000000116 DAPI staining Methods 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
102100020880 Kit ligand Human genes 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
108091027974 Mature messenger RNA Proteins 0.000 description 1
241000699673 Mesocricetus auratus Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000713869 Moloney murine leukemia virus Species 0.000 description 1
108090000143 Mouse Proteins Proteins 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
206010028116 Mucosal inflammation Diseases 0.000 description 1
101100233764 Mus musculus Jak1 gene Proteins 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
238000002123 RNA extraction Methods 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
108010039445 Stem Cell Factor Proteins 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
108091081400 Subtelomere Proteins 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
210000001766 X chromosome Anatomy 0.000 description 1
210000002593 Y chromosome Anatomy 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000011481 absorbance measurement Methods 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000036428 airway hyperreactivity Effects 0.000 description 1
230000010085 airway hyperresponsiveness Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000006368 anti-apoptosis response Effects 0.000 description 1
230000002424 anti-apoptotic effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
230000007503 antigenic stimulation Effects 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000007640 basal medium Substances 0.000 description 1
230000037429 base substitution Effects 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
238000010170 biological method Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000004044 bronchoconstricting agent Substances 0.000 description 1
230000007885 bronchoconstriction Effects 0.000 description 1
230000003435 bronchoconstrictive effect Effects 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000002737 cell proliferation kit Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000007398 colorimetric assay Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
102000003675 cytokine receptors Human genes 0.000 description 1
108010057085 cytokine receptors Proteins 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
108091092330 cytoplasmic RNA Proteins 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
238000000586 desensitisation Methods 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
229940112141 dry powder inhaler Drugs 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003344 environmental pollutant Substances 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
210000003013 erythroid precursor cell Anatomy 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000001400 expression cloning Methods 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000000943 fetal thymocyte Anatomy 0.000 description 1
239000012997 ficoll-paque Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
238000013412 genome amplification Methods 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000000971 hippocampal effect Effects 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
102000051950 human IL9R Human genes 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
210000003917 human chromosome Anatomy 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000005934 immune activation Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
239000012133 immunoprecipitate Substances 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000002664 inhalation therapy Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229940076264 interleukin-3 Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000010212 intracellular staining Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
238000000670 ligand binding assay Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
230000021121 meiosis Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229920002113 octoxynol Polymers 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
238000002823 phage display Methods 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
231100000719 pollutant Toxicity 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229940124606 potential therapeutic agent Drugs 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000001902 propagating effect Effects 0.000 description 1
239000003531 protein hydrolysate Substances 0.000 description 1
201000009732 pulmonary eosinophilia Diseases 0.000 description 1
235000021251 pulses Nutrition 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
210000003370 receptor cell Anatomy 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
239000003161 ribonuclease inhibitor Substances 0.000 description 1
239000012146 running buffer Substances 0.000 description 1
238000009738 saturating Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
239000011669 selenium Substances 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000011775 sodium fluoride Substances 0.000 description 1
235000013024 sodium fluoride Nutrition 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
108091005990 tyrosine-phosphorylated proteins Proteins 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Analytical Chemistry (AREA)
Wood Science & Technology (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Pathology (AREA)
Toxicology (AREA)
Cell Biology (AREA)
Gastroenterology & Hepatology (AREA)
Medicinal Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

JP52573798A 1996-12-02 1997-12-02 喘息および関連疾患を含むアトピー性アレルギーの治療および診断に有用なｉｌ−９受容体変異体 Expired - Fee Related JP4552076B2 (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US3222496P	1996-12-02	1996-12-02
US60/032,224		1996-12-02
US98087297A	1997-12-01	1997-12-01
US08/980,872		1997-12-01
PCT/US1997/021992 WO1998024904A2 (en)	1996-12-02	1997-12-02	Il-9 receptor variants, useful in treating and diagnosing atopic allergies including asthma and related disorders

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2009048597A Division JP2009159976A (ja)	1996-12-02	2009-03-02	喘息および関連疾患を含むアトピー性アレルギーの治療および診断に有用なｉｌ−９受容体変異体

Publications (3)

Publication Number	Publication Date
JP2002514911A JP2002514911A (ja)	2002-05-21
JP2002514911A5 JP2002514911A5 (de)	2005-08-11
JP4552076B2 true JP4552076B2 (ja)	2010-09-29

Family

ID=26708147

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP52573798A Expired - Fee Related JP4552076B2 (ja)	1996-12-02	1997-12-02	喘息および関連疾患を含むアトピー性アレルギーの治療および診断に有用なｉｌ−９受容体変異体
JP2009048597A Pending JP2009159976A (ja)	1996-12-02	2009-03-02	喘息および関連疾患を含むアトピー性アレルギーの治療および診断に有用なｉｌ−９受容体変異体

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2009048597A Pending JP2009159976A (ja)	1996-12-02	2009-03-02	喘息および関連疾患を含むアトピー性アレルギーの治療および診断に有用なｉｌ−９受容体変異体

Country Status (8)

Country	Link
EP (1)	EP0942979A2 (de)
JP (2)	JP4552076B2 (de)
AT (1)	ATE471982T1 (de)
AU (1)	AU746595B2 (de)
CA (1)	CA2271952C (de)
DE (1)	DE69739920D1 (de)
ES (1)	ES2347962T3 (de)
PT (1)	PT1471144E (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN119040500B (zh) *	2024-07-18	2026-04-17	中国农业科学院作物科学研究所	与大豆种子油份、蛋白含量和百粒重相关的snp分子标记与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2666298A1 (en) *	1995-08-24	1997-03-06	Genaera Corporation	Asthma associated factors as targets for treating atopic allergies including asthma and related disorders

1997
- 1997-12-02 EP EP97953072A patent/EP0942979A2/de not_active Withdrawn
- 1997-12-02 DE DE69739920T patent/DE69739920D1/de not_active Expired - Lifetime
- 1997-12-02 CA CA2271952A patent/CA2271952C/en not_active Expired - Fee Related
- 1997-12-02 AU AU56891/98A patent/AU746595B2/en not_active Ceased
- 1997-12-02 PT PT04013403T patent/PT1471144E/pt unknown
- 1997-12-02 JP JP52573798A patent/JP4552076B2/ja not_active Expired - Fee Related
- 1997-12-02 ES ES04013403T patent/ES2347962T3/es not_active Expired - Lifetime
- 1997-12-02 AT AT04013403T patent/ATE471982T1/de not_active IP Right Cessation
2009
- 2009-03-02 JP JP2009048597A patent/JP2009159976A/ja active Pending

Also Published As

Publication number	Publication date
DE69739920D1 (de)	2010-08-05
JP2002514911A (ja)	2002-05-21
AU5689198A (en)	1998-06-29
CA2271952C (en)	2010-04-06
ATE471982T1 (de)	2010-07-15
ES2347962T3 (es)	2010-11-26
CA2271952A1 (en)	1998-06-11
AU746595B2 (en)	2002-05-02
JP2009159976A (ja)	2009-07-23
PT1471144E (pt)	2010-08-17
EP0942979A2 (de)	1999-09-22

Legal Events

Date	Code	Title	Description
2004-12-24	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041202
2004-12-24	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041202
2008-09-02	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080902
2008-12-18	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081126
2009-01-09	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090109
2009-01-22	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081224
2009-02-09	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090209
2009-02-19	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090129
2009-03-09	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090309
2009-03-26	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090302
2009-11-10	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091110
2010-03-04	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100209
2010-03-19	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100319
2010-04-01	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100309
2010-04-19	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100419
2010-04-30	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100409
2010-05-24	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100524
2010-05-27	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100507
2010-06-04	TRDD	Decision of grant or rejection written
2010-06-15	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100615
2010-06-17	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2010-07-08	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100629
2010-07-23	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20130723 Year of fee payment: 3
2010-07-23	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2013-07-23	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
US7704710B2 (en)	2010-04-27	Interleukin-9 receptor mutants
US6645492B2 (en)	2003-11-11	Methods of treating asthma with interleukin-9 receptor antibodies
JP4813380B2 (ja)	2011-11-09	喘息および関連疾患を含むアトピー性アレルギーを治療するための標的としての喘息関連因子
WO1998024904A9 (en)	1998-10-01	Il-9 receptor variants, useful in treating and diagnosing atopic allergies including asthma and related disorders
EP1471144B1 (de)	2010-06-23	Biologische Variabilität von Asthma-assoziiertem Faktor 2 AAF2 (IL-9 Rezeptor) nützlich für die Behandlung und Diagnose von atopischen Allergien wie Asthma und Asthma-ähnlichen Erkrankungen
CA2271952C (en)	2010-04-06	Il-9 receptor variants, useful in treating and diagnosing atopic allergies including asthma and related disorders
AU752735B2 (en)	2002-09-26	Asthma and related disorders
AU2010241326A1 (en)	2010-12-02	Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
AU2011265475A1 (en)	2012-01-19	Asthma associated factors as targets for treating atopic allergies including asthma and related disorders